Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

Latest News

Asian markets lower, oil rises on Iran concerns

Apr 22, 2019

BEIJING — Asian stock markets were mostly lower while oil prices surged for a second day Monday following reports Washington wants to block Iranian exports. Tokyo's benchmark edged up while Shanghai, Seoul and India retreated. Hong Kong and Sydney were closed for the holiday. On Wall Street, the benchmark Standard & Poor's 500 index ended a shortened trading week Thursday snapping a winning streak of three weekly gains. Investors looked ahead to U.S. quarterly gross domestic product due out Friday. Also this week, the United States reports new home sales Tuesday while Japan announces factory output on Friday. "The broad...

New indictment expands case against Nissan ex-chair Ghosn

Apr 22, 2019

TOKYO — Japanese prosecutors said Monday they have indicted Nissan's former chairman Carlos Ghosn with additional charges of breach of trust, with his alleged misconduct expanding further outside Japan. The charges filed Monday are his fourth. They are related to payments by a subsidiary of the Japanese automaker that allegedly went to a private investment company controlled by Ghosn. Prosecutors would not confirm details of the charges. The indictment was expected and it ensures he will remain in detention longer. His current period of detention would have expired Monday if he had not been charged. Ghosn, 65, was arrested in...

China's Huawei says 1Q sales up 39%

Apr 22, 2019

BEIJING — Chinese tech giant Huawei said Monday its revenue rose 39% over a year earlier in the latest quarter despite U.S. pressure on allies to shun its telecom technology as a security risk. Huawei, the biggest global maker of network equipment for phone and internet companies, on Monday reported revenue of 179.7 billion yuan ($26.8 billion) for the first three months of the year. Washington's pressure on allies to avoid Huawei, China's first global tech brand, threatens to block access to Europe and other markets as carriers prepare to invest billions of dollars in next-generation technology. The company denies...

Asian markets mixed in post-Easter trading

Apr 22, 2019

BEIJING — Asian stock markets were mixed Monday following the Easter holiday weekend as investors looked ahead to U.S. and Japanese economic data. Benchmarks in Tokyo and Seoul gained while Shanghai retreated. Hong Kong and Sydney were closed for the holiday. On Wall Street, the benchmark Standard & Poor's 500 index ended a shortened trading week on Thursday snapping a winning streak of three weekly gains. Investors looked ahead to U.S. quarterly gross domestic product due out Friday. The United States reports new home sales Tuesday while Japan announces factory output on Friday. "The broad expectation is for U.S. indices...

Liverpool returns to top spot; Everton humiliates Man United

Apr 22, 2019

LONDON — Before returning to the top of the Premier League, Liverpool got to savor a Manchester United humiliation. Now, unusually, Liverpool needs a swift recovery by its great rival after United's despair at being routed 4-0 by Everton on Sunday. Liverpool's hopes of ending a 29-year English title drought could hinge on a big favor from sixth-place United when it hosts Manchester City on Wednesday. After beating Cardiff 2-0 on Sunday, Liverpool is two points ahead of City with three games remaining. But Pep Guardiola's champions have a game in hand over Liverpool so defending the title is still...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!